文献速递毛发、甲与色素性疾病

欧洲、日本和美国成人白癜风患病率与生活质量调查

Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-06-14

该调查通过欧洲、日本和美国的在线小组招募≥18岁参与者,估计白癜风总患病率为1.3%(已诊断0.6%、未诊断0.4%、有白癜风体征0.3%)。在219例正式诊断患者中,VitiQoL总分与年龄、疾病范围、进展、管理和诊断后时间相关;头部及头手/腕部皮损者总分更高。

要点

  • 35 694名参与者中白癜风总患病率为1.3%,其中已诊断0.6%、未诊断0.4%、有体征0.3%。
  • 219例正式诊断患者中,VitiQoL总分与年龄、疾病范围、进展、管理及诊断后时间相关。
  • 头部皮损及头手/腕部皮损患者的总VitiQoL评分更高。

核心结论

  • 白癜风患病率可能高于既往报告,相当比例归因于未获得正式诊断者。
  • 在正式诊断的白癜风患者中,生活质量受疾病进展程度和范围影响最严重。

研究设计与样本

  • 基于人群的多国在线调查,在欧洲、日本和美国招募≥18岁参与者。
  • 总分析样本35 694人(欧洲n=18 785;美国n=8 517;日本n=8 392)。
  • 正式诊断白癜风患者219例(欧洲n=150;美国n=48;日本n=21)接受VitiQoL等更广泛调查。

主要发现

  • 总估计白癜风患病率为1.3%(已诊断0.6%;未诊断0.4%;有白癜风体征0.3%)。
  • VitiQoL总分与年龄(P=0.00017)、疾病范围(P<0.0001)、疾病进展(P<0.0001)、疾病管理(P<0.0001)及诊断后时间(P=0.0015)相关。
  • 行为评分随皮肤光型(P=0.024)和族裔(P=0.048)变化。
  • 头部皮损患者(P=0.027)及头部和手和/或腕部皮损患者(P=0.018)报告更高的总VitiQoL评分。
  • 所有身体部位均存在对皮损的高度担忧(11点Likert量表评分8-10),且随地理区域变化。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Vitiligo, an autoimmune disorder characterised by skin depigmentation, is associated with reduced quality of life (QoL). Vitiligo may be under-reported, in part because of misconceptions that it is a cosmetic disease. OBJECTIVES: This survey sought to characterise vitiligo prevalence and explore the relationship between sociodemographic and clinical characteristics with QoL in a population-based, multinational study. METHODS: Participants aged ≥18 years were recruited via an online panel in Europe, Japan and the USA to answer questions regarding skin disorders they may have experienced. Those reporting vitiligo (diagnosed or undiagnosed) or vitiligo signs (experiencing loss of skin colour but unaware of vitiligo and not diagnosed) were included in the analyses of vitiligo prevalence. Participants who self-reported physician-diagnosed vitiligo were given a broader survey to characterise disease progression, management and QoL (as measured with the Vitiligo-specific QoL [VitiQoL] instrument). RESULTS: The total estimated vitiligo prevalence among 35 694 survey participants (Europe, n = 18 785; USA, n = 8517; Japan, n = 8392) was 1.3% (diagnosed, 0.6%; undiagnosed, 0.4%; vitiligo signs, 0.3%). Among 219 patients formally diagnosed with vitiligo (Europe, n = 150; USA, n = 48; Japan, n = 21), total VitiQoL scores were associated with age (P = 0.00017), disease extent (P < 0.0001), disease progression (P < 0.0001), disease management (P < 0.0001) and time since diagnosis (P = 0.0015). Behaviour scores varied based on skin phototype (P = 0.024) and ethnicity (P = 0.048). Higher total VitiQoL scores were reported in patients with head lesions (P = 0.027) and those with head and hand and/or wrist lesions (P = 0.018). Substantial high concern (rated 8-10 on an 11-point Likert scale) for lesions was found across all body areas and varied with geographical region. CONCLUSIONS: The vitiligo prevalence rate may be higher than previously reported, with a substantial proportion attributed to people who have not received a formal diagnosis. Among formally diagnosed patients with vitiligo, QoL was most severely impacted by more progressive and higher extent of disease.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol. 2022. PMID: 35611638. doi:10.1111/jdv.18257

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。